Analyst Price Targets — CYRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 1:27 pm | — | Needham | $19.00 | $14.71 | TheFly | Cryoport price target raised to $19 from $15 at Needham |
| August 7, 2026 11:33 am | Subbu Nambi | Guggenheim | $16.00 | $14.71 | TheFly | Cryoport price target raised to $16 from $12 at Guggenheim |
| August 7, 2026 10:18 am | Richard Baldry | Roth Capital | $21.00 | $14.71 | TheFly | Cryoport price target raised to $21 from $15 at Roth Capital |
| July 24, 2026 11:33 am | — | BTIG | $25.00 | $16.03 | TheFly | Cryoport price target raised to $25 from $17 at BTIG |
| June 8, 2026 7:37 pm | Matthew Stanton | Jefferies | $13.50 | $15.48 | TheFly | Cryoport price target raised to $13.50 from $11 at Jefferies |
| June 8, 2026 7:33 pm | Matthew Stanton | Jefferies | $13.00 | $15.48 | TheFly | Cryoport price target raised to $13 from $11 at Jefferies |
| June 3, 2026 12:45 pm | Matthew Hewitt | Craig-Hallum | $20.00 | $16.10 | TheFly | Cryoport price target raised to $20 from $15 at Craig-Hallum |
| May 20, 2026 10:24 am | Paul Knight | KeyBanc | $17.00 | $13.03 | TheFly | Cryoport price target raised to $17 from $15 at KeyBanc |
| May 5, 2026 12:27 pm | — | Needham | $15.00 | $12.14 | TheFly | Cryoport price target raised to $15 from $13 at Needham |
| May 5, 2026 11:30 am | — | BTIG | $17.00 | $10.21 | TheFly | Cryoport price target raised to $17 from $15 at BTIG |
Latest News for CYRX
CryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript
CryoPort NASDAQ: CYRX reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations, while reaffirming its full-year revenue outlook of $192 million to $196 million.
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.29 per share a year ago.
Second quarter revenue grew 8% year-over-year to $49.0 million Life Sciences Services revenue increased 15% year-over-year BioStorage/BioServices revenue grew 25% year-over-year Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of June 30, 2026 NASHVILLE, Tenn., Aug. 6, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CYRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.